Insulin Resistance: The Increased Risk of Cancers

• Published in: Current oncology (Toronto) 2024-02, Vol.31 (2), p.998-1027
• Main Author: Szablewski, Leszek
• Format: Article
• Language: English
• Subjects: Adipose tissues; Amino acids; Blood sugar; cancers; Development and progression; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - metabolism; Health aspects; Humans; Hyperinsulinism - complications; Hyperinsulinism - metabolism; Hypoglycemic agents; Insulin; insulin cellular signaling; Insulin resistance; Insulin Resistance - physiology; insulin-like growth factors; Liver; Liver cancer; Neoplasm Recurrence, Local; Obesity; Obesity - complications; Risk factors; Type 2 diabetes
• ISSN: 1718-7729; 1198-0052; 1718-7729
• DOI: 10.3390/curroncol31020075

Insulin resistance, also known as impaired insulin sensitivity, is the result of a decreased reaction of insulin signaling to blood glucose levels. This state is observed when muscle cells, adipose tissue, and liver cells, improperly respond to a particular concentration of insulin. Insulin resistance and related increased plasma insulin levels (hyperinsulinemia) may cause metabolic impairments, which are pathological states observed in obesity and type 2 diabetes mellitus. Observations of cancer patients confirm that hyperinsulinemia is a major factor influencing obesity, type 2 diabetes, and cancer. Obesity and diabetes have been reported as risks of the initiation, progression, and metastasis of several cancers. However, both of the aforementioned pathologies may independently and additionally increase the cancer risk. The state of metabolic disorders observed in cancer patients is associated with poor outcomes of cancer treatment. For example, patients suffering from metabolic disorders have higher cancer recurrence rates and their overall survival is reduced. In these associations between insulin resistance and cancer risk, an overview of the various pathogenic mechanisms that play a role in the development of cancer is discussed.